MA50418A - Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse - Google Patents
Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèseInfo
- Publication number
- MA50418A MA50418A MA050418A MA50418A MA50418A MA 50418 A MA50418 A MA 50418A MA 050418 A MA050418 A MA 050418A MA 50418 A MA50418 A MA 50418A MA 50418 A MA50418 A MA 50418A
- Authority
- MA
- Morocco
- Prior art keywords
- synthesis
- salts
- methods
- substituted heterocyclic
- heterocyclic compounds
- Prior art date
Links
- -1 AMINE SUBSTITUTED HETEROCYCLIC COMPOUNDS Chemical class 0.000 title 1
- 102100035042 Histone-lysine N-methyltransferase EHMT2 Human genes 0.000 title 1
- 101000877312 Homo sapiens Histone-lysine N-methyltransferase EHMT2 Proteins 0.000 title 1
- 230000015572 biosynthetic process Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 238000003786 synthesis reaction Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762573917P | 2017-10-18 | 2017-10-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50418A true MA50418A (fr) | 2021-04-07 |
Family
ID=66173899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050418A MA50418A (fr) | 2017-10-18 | 2018-10-18 | Composés hétérocycliques substitués par une amine, utilisés comme inhibiteurs de l'ehmt2, sels de ceux-ci, et leurs méthodes de synthèse |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20200247790A1 (enExample) |
| EP (1) | EP3697762A4 (enExample) |
| JP (2) | JP2021500334A (enExample) |
| KR (1) | KR20200101330A (enExample) |
| CN (1) | CN111417628A (enExample) |
| AU (2) | AU2018353122B2 (enExample) |
| BR (1) | BR112020007632A2 (enExample) |
| CA (1) | CA3079273A1 (enExample) |
| CL (1) | CL2020001009A1 (enExample) |
| CO (1) | CO2020005944A2 (enExample) |
| EA (1) | EA202090959A1 (enExample) |
| IL (2) | IL301746B2 (enExample) |
| MA (1) | MA50418A (enExample) |
| MX (2) | MX2020007152A (enExample) |
| SG (1) | SG11202003225YA (enExample) |
| WO (1) | WO2019079540A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110446495B (zh) | 2017-02-17 | 2023-09-05 | 特维娜有限公司 | 含有7元氮杂杂环的δ阿片受体调节化合物及其使用和制备方法 |
| WO2018195450A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN114249785B (zh) * | 2020-09-23 | 2024-04-05 | 常州方圆制药有限公司 | 一种2-腺苷n-吡唑的衍生物瑞加德松的制备方法 |
| CN116406268A (zh) * | 2020-10-27 | 2023-07-07 | 特维娜有限公司 | δ-阿片样物质调节剂的结晶和无定形形式 |
| WO2025240956A1 (en) * | 2024-05-17 | 2025-11-20 | Yale University | G9a/ehmt2 inhibitor use for prader-willi syndrome |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004272288B2 (en) * | 2003-09-18 | 2008-11-13 | Novartis Ag | 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders |
| WO2007053452A1 (en) * | 2005-11-01 | 2007-05-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US9284272B2 (en) * | 2014-03-28 | 2016-03-15 | Abbvie Inc. | Inhibitors of histone methyltransferase G9a |
| DK3154957T3 (da) * | 2014-06-16 | 2020-02-17 | Fundacion Para La Investig Medica Aplicada | Hidtil ukendte forbindelser som dobbelte inhibitorer af histonmethyltransferaser og dna-methyltransferaser |
| JP2017519017A (ja) * | 2014-06-23 | 2017-07-13 | ジェネンテック， インコーポレイテッド | 癌の治療及び癌薬剤耐性の防止方法 |
| IL307931A (en) * | 2016-04-15 | 2023-12-01 | Epizyme Inc | Amine-substituted aryl or heteroaryl compounds as ehmt1 and ehmt2 inhibitors |
| MA47233A (fr) * | 2016-12-19 | 2019-10-23 | Epizyme Inc | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation |
| AU2018243749A1 (en) * | 2017-03-31 | 2019-11-21 | Epizyme, Inc. | Methods of using EHMT2 inhibitors |
| US20210213014A1 (en) * | 2017-10-18 | 2021-07-15 | Epizyme, Inc. | Methods of using ehmt2 inhibitors in immunotherapies |
-
2018
- 2018-10-18 MX MX2020007152A patent/MX2020007152A/es unknown
- 2018-10-18 KR KR1020207013781A patent/KR20200101330A/ko not_active Ceased
- 2018-10-18 BR BR112020007632-5A patent/BR112020007632A2/pt unknown
- 2018-10-18 SG SG11202003225YA patent/SG11202003225YA/en unknown
- 2018-10-18 CA CA3079273A patent/CA3079273A1/en active Pending
- 2018-10-18 EP EP18869308.9A patent/EP3697762A4/en not_active Withdrawn
- 2018-10-18 EA EA202090959A patent/EA202090959A1/ru unknown
- 2018-10-18 MA MA050418A patent/MA50418A/fr unknown
- 2018-10-18 US US16/756,565 patent/US20200247790A1/en not_active Abandoned
- 2018-10-18 CN CN201880077022.4A patent/CN111417628A/zh active Pending
- 2018-10-18 JP JP2020521599A patent/JP2021500334A/ja not_active Withdrawn
- 2018-10-18 AU AU2018353122A patent/AU2018353122B2/en not_active Ceased
- 2018-10-18 IL IL301746A patent/IL301746B2/en unknown
- 2018-10-18 WO PCT/US2018/056428 patent/WO2019079540A1/en not_active Ceased
-
2020
- 2020-04-15 CL CL2020001009A patent/CL2020001009A1/es unknown
- 2020-04-16 IL IL273974A patent/IL273974B2/en unknown
- 2020-05-15 CO CONC2020/0005944A patent/CO2020005944A2/es unknown
- 2020-07-13 MX MX2024012124A patent/MX2024012124A/es unknown
-
2022
- 2022-03-24 US US17/703,155 patent/US20220324851A1/en not_active Abandoned
-
2023
- 2023-01-11 JP JP2023002371A patent/JP2023036991A/ja active Pending
-
2024
- 2024-02-22 AU AU2024201165A patent/AU2024201165A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20220324851A1 (en) | 2022-10-13 |
| AU2018353122A1 (en) | 2020-06-04 |
| IL301746A (en) | 2023-05-01 |
| IL301746B2 (en) | 2025-01-01 |
| JP2021500334A (ja) | 2021-01-07 |
| CO2020005944A2 (es) | 2020-07-31 |
| MX2024012124A (es) | 2025-02-10 |
| IL273974B1 (en) | 2023-04-01 |
| CA3079273A1 (en) | 2019-04-25 |
| AU2018353122B2 (en) | 2023-11-23 |
| SG11202003225YA (en) | 2020-05-28 |
| KR20200101330A (ko) | 2020-08-27 |
| JP2023036991A (ja) | 2023-03-14 |
| MX2020007152A (es) | 2020-12-10 |
| CN111417628A (zh) | 2020-07-14 |
| BR112020007632A2 (pt) | 2020-09-29 |
| US20200247790A1 (en) | 2020-08-06 |
| EP3697762A1 (en) | 2020-08-26 |
| WO2019079540A1 (en) | 2019-04-25 |
| EA202090959A1 (ru) | 2020-07-13 |
| AU2024201165A1 (en) | 2024-03-14 |
| CL2020001009A1 (es) | 2020-12-18 |
| IL301746B1 (en) | 2024-09-01 |
| EP3697762A4 (en) | 2021-04-07 |
| IL273974B2 (en) | 2023-08-01 |
| IL273974A (en) | 2020-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA47233A (fr) | Composés hétérocycliques substitués par une amine utilisés comme inhibiteurs de l'ehmt2 et leurs méthodes d'utilisation | |
| EP3402799A4 (en) | Heterocyclic compounds as RSV inhibitors | |
| MA51846A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de kinases | |
| MA51438A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1 | |
| EP3389783A4 (en) | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| MA55633A (fr) | Salicylamides de spiroheptane et composés associés utilisés comme inhibiteurs de rock | |
| MA46045A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA45669A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MX378499B (es) | Compuestos antifungicos. | |
| MA44860A (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MX383935B (es) | Amidas heterocíclicas como inhibidores de cinasa. | |
| MA40301B1 (fr) | Composés indolecarboxamides utiles comme inhibiteurs de kinase | |
| MA46531A (fr) | Dérivés d'azétidine ou de cyclobutane 1,3-disubstitués utilisés comme inhibiteurs de la prostaglandine d synthase hématopoïétique (h-pgds) | |
| EP3331880A4 (en) | N- (PYRIDIN-2-YL) -4- (THIAZOL-5-YL) PYRIMIDIN-2-AMINE DERIVATIVES AS THERAPEUTIC COMPOUNDS | |
| MA50609A (fr) | Énantiomères de thiazoles substitués utilisés comme composés antiviraux | |
| MA49374A (fr) | Composés hétéroaromatiques utilisés en tant qu'inhibiteurs de vanine | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EP3666770A4 (en) | NEW HETEROCYCLIC COMPOUNDS AS CDK8 / 19 INHIBITORS | |
| EA201791684A1 (ru) | Селективные ингибиторы bace1 | |
| MA40302A1 (fr) | Dérivés de carbazole | |
| MA51864A (fr) | Méthodes d'identification de composés | |
| MX394835B (es) | Metodos para la preparacion de compuestos heterociclicos de 1,3-benzodioxol. | |
| EA201690523A1 (ru) | Триазолопиридины, композиции и способы их применения | |
| MA40250A (fr) | Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k |